
AVLN
Healthcare · Biotechnology · $1.35B market cap
$30.28-0.31 (-1.0%)Nov 13, 4:00 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -46.9% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 3 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | Before the open | -0.64 | -0.67 | -4.7% |
| Aug 12, 2026 | Before the open | -1.03 | -0.98 | +4.9% |
| Jun 3, 2026 | Before the open | -0.81 | -21.83 | -2595.1% |
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of…